BREAST CANCER

Aditya Bardia, MD, MPH, Attending Physician, Massachusetts General Hospital, Harvard Medical School, gives an overview of the Snapshot assay for breast cancer.

Women with DCIS treated with radiation therapy had no increased risk of cardiovascular disease compared with women in the general population or women with DCIS treated with surgery.

Patients with DCIS who received an MRI added to mammography before or immediately after receiving a lumpectomy did not experience an improvement in the rate of disease recurrence.

Naomi B. Boekel, MSc, discusses the results from a large study that showed that radiation therapy for DCIS does not seem to increase cardiovascular disease risk.

Deanna J. Attai, MD, surgeon, president, Center For Breast Care, Burbank, CA, discusses patients' perception of breast cancer risk.

Despite recent oncology breakthroughs, conventional anticancer treatments may have limitations. Decades of research are resulting in the capacity to create a new generation of antibody drug conjugates.

Andrew D. Seidman, MD, from Memorial Sloan-Kettering Cancer Center, discusses breast cancer treatment with surgery and radiotherapy.

Kathy S. Albain, MD, from Loyola University Chicago, discusses gene assays as they relate to the treatment of patients with breast cancer.

Paul A. Bunn, Jr, MD, from the University of Colorado, discusses afatinib for patients with activating epidermal growth factor receptor mutation.

Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the difficulties with a gold standard clinical trial endpoint in ovarian cancer.

Elizabeth Mittendorf, MD, PhD, from the University of Texas MD Anderson Cancer Center, gives an overview of how the E75 vaccine works in breast cancer.

Breast cancer pathogenesis may be driven by activation of steroid hormone receptors, like those for estrogen and progesterone, and may also be driven by receptor tyrosine kinases.

Dual HER2-targeted neoadjuvant therapy for early breast cancer did not significantly improve the pCR rate compared with a single anti-HER2 agent plus chemotherapy.

Adding everolimus to conventional therapy slowed the progression of trastuzumab-resistant advanced breast cancer and provided clues to the origin of trastuzumab resistance.

Minetta Liu, MD, Breast Cancer Specialist, Mayo Clinic, Rochester, Minnesota, describes the CELLSEARCH® CTC Test, which allows for an assessment of patient prognosis.

At the 18th Annual Conference of the National Comprehensive Cancer Network (NCCN), experts presented the latest updates to the NCCN Clinical Practice Guidelines in Oncology.

Debu Tripathy, MD, from the Norris Comprehensive Cancer Center, discusses the treatment of breast cancer with anthracyclines and trastuzumab.

Tamoxifen significantly lowered the risk of contralateral or secondary breast cancer by more than half in patients with BRCA1/2 mutations.

Max S. Wicha, MD, was part of the first team to discover stem cells in breast cancer, and he is among the most highly cited investigators in the field of cancer stem cells.

Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses targeting the androgen receptor in breast cancer.

Jane E. Churpek, MD, medical oncologist, hematologist, The University of Chicago, discusses the ATM, CHEK2, and PTEN genes in breast cancer.

Hope S. Rugo, MD, from the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses pathway changes in breast cancer.

Sandra Swain, MD, medical director of the Washington Cancer Institute at MedStar Washington Hospital Center, gives an overview of the next steps for pertuzumab in breast cancer.

Torsten O. Nielsen, MD, PhD, FRCPC, professor, pathology, University of British Columbia, discusses Ki67 in breast cancer.

Richard Finn, MD, from UCLA, discusses the treatment of patients with estrogen receptor-positive (ER+) breast cancer with antiestrogens.